Journal of Pharmaceutical Care & Health Systems
Open Access
ISSN: 2376-0419
+44 1300 500008
ISSN: 2376-0419
+44 1300 500008
Jean G Sathish
University of Liverpool, UK
Posters-Accepted Abstracts: J Pharma Care Health Sys
Immunomodulatory biologics are a major focus of drug development with a variety of clinical indications including cancers and autoimmunity. However, these biopharmaceuticals are associated a risk of serious adverse effects such as cytokine release syndromes (cytokine storm), infection, immunogenicity and autoimmunity. This is dramatically exemplified by the near-fatal cytokine storm induced in human volunteers in a Phase I clinical trial with the immunomodulatory biologic, TGN1412. Detailed understanding of the target biology followed by identification and screening of target specific biomarkers for risk assessment is essential for the development of safe immunomodulatory biologics. Recent work in our laboratory has focussed on defining the cellular and molecular basis for T cell dysregulation induced by TGN1412. Our results reveal that critical elements of T cell co-inhibitory pathways are dysregulated in TGN1412-activated T cells. We have also identified central changes in T cell metabolism and bioenergetics that underlie and drive the dysregulation. The background to this area and our findings will be discussed in the talk.
Email: Jean.Sathish@liverpool.ac.uk